Viral Hepatitis C - Robust Viral Load Reduction Successfully Achieved In Phase II Clinical Trial Of ANA380 In Lamivudine-Resistant,

Robust Viral Load Reduction Successfully Achieved In Phase II Clinical Trial Of ANA380 In Lamivudine-Resistant,
Medical News Today - Feb 15 12:03 PM
AnadysPharmaceuticals, Inc. (Nasdaq: ANDS) and L.G. Life Sciences, Ltd. announced principalfindings from an open label, multi-center, dose-escalation Phase II clinicaltrial, evaluating the safety and antiviral activity of ANA380 (LB80380) inpatients with lamivudine-resistant hepatitis B virus (HBV) infection... click link for more info.Save to My Web

West Coast Editor
BioWorld - Feb 15 9:02 PM
Anadys Pharmaceuticals Inc. and South Korean co-developer L.G. Life Sciences Ltd. reported strong data from a Phase II trial with ANA380 against chronic hepatitis B virus, a compound for which Novartis AG holds a license option.Save to My Web

Schering-Plough Reports FDA Grants Fast Track Designation to Oral HCV Protease Inhibitor SCH 503034
[Press Release] PR Newswire via Yahoo! Finance - Jan 30 6:18 AM
Schering-Plough today reported that the U.S. Food and Drug Administration has granted Fast Track designation to its investigational oral hepatitis C protease inhibitor , currently in Phase II clinical development for the treatment of chronic hepatitis C virus infection.Save to My Web

Ashok Leyland: On a roll
Business Standard India - Feb 10 10:32 AM
Ashok Leylands numbers for Q3 FY06 surprised the street mainly because the 22 per cent y-o-y top line growth comprised a value increase of around 20 per cent, on a volume growth of just 1.6 per cent y-o-y.Save to My Web

Chiron partners with Portland's AVI
San Francisco Business Times - Jan 30 10:23 AM
Chiron Corp. and AVI BioPharma Inc. made an agreement granting AVI a nonexclusive license to Chiron's patents and patent applications for the research, development and commercialization of drugs that fight the hepatitis C virus (HCV).Save to My Web